OR-OPEN19-FOUNDATION
4.6.2019 12:02:07 CEST | Business Wire | Press release
The Open19 Foundation, an organization established to create a community for a new generation of open data centers and edge solutions, today announced its membership within the Kinetic Edge™ Alliance (KEA) as a technology partner. The future of computing is at the edge, and this partnership will accelerate deployment of Open19 infrastructure into edge locations.
“The Kinetic Edge Alliance is the de-facto alliance that is creating order and a blueprint to build the edge technology specifically for edge cloud applications,” said Yuval Bachar, Open19 Foundation President. “The Open19 Foundation will join the Kinetic Edge Alliance to add the hardware buildout building block to the alliance with the Open19 platform. The Open19 platform is designed for the edge and optimized for the solution as defined by the Kinetic Edge alliance. It will enable a standard but flexible solution for building the Edge platforms of the present and the future.”
Founded by Open19 Foundation member company Vapor IO , the Kinetic Edge Alliance is an industry working group dedicated to making edge computing easy and connecting stakeholders with end users and customers. Other members of the group include Packet, New Continuum Data Centers, and Seagate. Learn more about the Alliance here .
“The Open19 standard makes it fast and economical to deploy equipment in edge environments,” said Matt Trifiro, CMO of Vapor IO. “By offering a chassis design that slides in and out of a rack, installing or swapping out data center equipment becomes almost as easy as opening and closing a desk drawer. This makes it possible for technicians to deploy or repair edge equipment in minutes instead of hours or days.”
Twelve partner companies launched the Kinetic Edge Alliance in February 2019 for the purpose of driving broad adoption of compute, storage, access and interconnection at the edge of the cellular network, simplifying edge computing for the masses. The Alliance is actively rolling out equipment and services across the top 30 major metropolitan US markets, beginning with the first six markets in 2019. The Alliance seeks to deploy, in lockstep, all of the key hardware and software infrastructure components that will enable commercial-grade edge computing at scale. There are now nearly 40 partner companies in the Alliance.
About the Open19 Foundation
The Open19 Foundation was established in 2017 by founding members Flex, GE Digital, Hewlett Packard Enterprise, LinkedIn, Packet, and Vapor IO to create a community that will enable a common optimized data center and edge solutions. It has since grown to 26 members from all parts of the edge ecosystem – from component and system suppliers and integrators, to data center operators. For more information, visit the Foundation’s website at www.open19.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005313/en/
Contact:
Open19 Foundation Rachael Watson, PR manager rwatson@nereus-worldwide.com (971) 706-1312
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom